Active	Status	Sponsor type	Region	Phase	Filter
4 Active 2 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Gruijl, Tanja D de
INTRIM, NCT04126876: A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma Data from INTRIM study for melanoma May 2022 - May 2022: Data from INTRIM study for melanoma	Recruiting	2	214	Europe	Tilsotolimod, IMO-2125, Saline (0.9% sodium chloride), Placebo	A.J.M. van den Eertwegh, Idera Pharmaceuticals, Inc.	Malignant Melanoma	11/21	11/31
ITHACA, NCT06095674: ImmunoTHerapy Adjacent to Cervical CAncer () Study	Not yet recruiting	1	30	Europe	Anti-PD-1 antibody balstilimab, Anti-CTLA-4 antibody botensilimab	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Dutch Cancer Society, Agenus Inc.	Cervical Cancer	01/26	01/26
Eertwegh, Alfons van den
INTRIM, NCT04126876: A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma Data from INTRIM study for melanoma May 2022 - May 2022: Data from INTRIM study for melanoma	Recruiting	2	214	Europe	Tilsotolimod, IMO-2125, Saline (0.9% sodium chloride), Placebo	A.J.M. van den Eertwegh, Idera Pharmaceuticals, Inc.	Malignant Melanoma	11/21	11/31